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ABSTRACT 
Hypoactive sexual desire disorder (HSDD) is a persistent or recurrent deficiency or absence of sexual desire. It can cause prominent 
distress and interpersonal difficulty of women. There have been drugs available to treat sexual disorders in men when there is no 
such drug for women. Nowadays, FDA approved Flibanserin to treat HSDD of premenopausal women. This drug Flibanserin has no 
novel mechanism of action but the possible mechanism of action is modulating serotonin and dopamine activity in brain parts as 
balance of these systems is significance for a normal sexual response. 
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INTRODUCTION 
In today era, where women are at par with men in every 
sphere of life, distress be it in relation to their 
professional life or personal life, it does prevail. 
Hypoactive sexual desire disorder (HSDD) which is 
characterized by persistent or recurrent deficiency or 
absence of sexual fantasies and desire for sexual activity 
is one such disorder which may arise due to personal 
distress
1
. This entity HSDD includes two further 
disorders, Female sexual arousal disorder (FSAD) and 
Female sexual interest arousal disorder (FSIAD) (FDA 
briefing document). In 2006, the women’s international 
study of Health and sexuality (WISH) assessed the 
prevalence of HSDD and found out 24-36% of women 
between 20 and 70 year of age had problems with low 
sexual desire
2
.Now the question which remains 
unanswered is, since there has been a line of drug 
coming upto treat such disorders in males, why much 
research work has not been found to treat the same 
problem in women. Complex physiology of female 
genital tract might come up as an answer, but does not 
suffice
3
. 
Finally a wonder drug with no novel mechanism of 
action, called Flibanserin has come up and has been 
approved by FDA in August 2015
4
. 
MECHANISM OF ACTION 
Flibanserin binds to 5 hydroxytryptamine (5HT1A) 
receptor and acts as an agonist and it also acts as 5HT2A 
receptor antagonist. It also has weak partial agonist 
activity at Dopamine (D4) receptor. The proposed 
mechanism of action refers to Kinsey dual control model 
of sexual response
5
. Various NT sex steroids are other 
hormones that have excitatory inhibitory on sexual 
response. Amongst NT, excitatory activity is driven by 
dopamine and noradrenaline while inhibitory activity is 
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driven by serotonin
6
. The balance of these systems is 
significance for a normal sexual response. By 
modulating serotonin and dopamine activity in brain 
parts, Flibanserin improves the balance in regulation of 
sexual response
7
.   
PHARMACOKINETICS 
Flibanserin is rapidly absorbed with 90%of dose 
reaching systemic circulation as drug itself or its 
metabolite. After oral administration, maximum plasma 
concentration (Cmax) is usually achieved in 45-60 
minutes. Absolute bioavailability following oral dosing 
is 33%. Food moderately affects the rate and extent of its 
absorption
8
. 
It is metabolized by CYP3A4and to minor extent by 
CYP2D6.It is excreted as conjugated metabolite via bile 
and kidney. Terminal t½ is approximately 12 hours
9
. 
DRUG INTERACTIONS 
Strong CYP3A4 and CYP2D6 inhibitors and inducers 
can alter the level of Flibanserin. Concomitant 
administration with alcohol increases the risk of 
somnolence, fatigue, orthostatic hypotension and 
syncope. Interaction with CYP3A4 inhibitor like 
fluconazole increases the risk of syncope and 
symptomatic hypotension
10
. 
ADVERESE DRUG REACTIONS 
Most common reported adverse events included 
dizziness, nausea, and tiredness, disturbance in sleep. 
Concomitant intake of alcohol with Flibanserin results in 
severely low blood pressure
11
. 
CLINICAL TRIALS 
The drug has faced many issues in the past regarding its 
approval. In 2010, approval was denied pertaining to 
inadequate risk-benefit ratio. In June 2015, USFDA 
advisory committee recommended approval of the 
drug
12
.In August 2015, FDA finally approved 
Flibanserin for the treatment of premenopausal women 
with low sexual desire that causes personnel distress or 
relationship difficulties. It was specially specified that it 
should not be used to treat low sexual desire caused by 
coexisting psychiatric or medical reasons.  There are 
four main randomized controlled trials done to get 
approval of FDA
13
.  
DAISY STUDY 
Premenopausal women with Hypoactive Sexual Desire 
Disorder (HSDD) were randomized and treated with 
doses of Flibanserin 25mg and 50mg twice daily and 
100mg once daily at night time or placebo for 24 weeks. 
The mean age of women is 35 years. Results showed 
that women receiving Flibanserin 50mg twice daily and 
100mg once daily considered that their HSDD had 
improved with treatment (44% and 47% respectively). 
Only 30% of women receiving placebo receivers 
consider improvement. It can be found that in 
premenopausal women suffering from HSDD, 
Flibanserin 100mg once daily was tolerated and showed 
statistically significant improvement in sexual desire, 
sexual function and decrease of sexual distress compared 
to placebo
14
. 
VIOLET STUDY 
Premenopausal women with HSDD were randomized 
and treated with Flibanserin 50mg, Flibanserin 100mg or 
placebo once daily dose at night time for 24 weeks. 
About 39% and 50% of women respectively receiving 
50mg and 100mg Flibanserin considered improvement 
when only 30% of women receiving placebo considered 
improvement
15
.  
BEGONIA STUDY 
Premenopausal women (mean age: 36.6 years) were 
randomized and given treatment with Flibanserin 100mg 
once daily dose at night time or placebo for duration of 
24 weeks. The 38% of women treated with Flibanserin 
considered marked improvement and also showed 
significant reductions in distress associated with sexual 
dysfunction. Only 28% of placebo group considered 
improvement
16
. 
SNOWDROP STUDY 
Postmenopausal women with HSDD were treated with 
Flibanserin 100mg once daily at night time or placebo 
for 24 weeks. The 37% of women treated with 
Flibanserin 100mg and 28% of women receiving 
placebo considered the improvement respectively
17
. 
DRUG ABUSE AND DEPENDECNCE 
There is no increase in drug-seeking behavior, misuse 
and abuse once marketed. The only possible abuse is 
that men can force their partner to take this medicine to 
increase their desire
18
. 
PRESENT STATUS 
Flibanserin is available as 100 mg tablet. The 
recommended dose is 100 mg taken one time a day at 
bedtime. It can be taken only at bedtime as it can 
increase the risk of low blood pressure, fainting attack, 
accidental injury and sleepiness
19
. 
CONCLUSION 
Hypoactive Sexual Desire Disorder (HSDD) is a 
woman’s ongoing lack of sexual interest or desire that 
causes prominent distress and interpersonal difficulty. 
Flibanserin is the first and only approved drug of FDA 
to treat Hypoactive Sexual Desire Disorder (HSDD) in 
premenopausal women
20
.  
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